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Evaluation and Validation of a Real-
Time Polymerase Chain Reaction Assay 
for Rapid Identification of Bacillus 
anthracis Supplement 
During the recent outbreak of bioterrorism-associated anthrax in the United 
States, 11 patients were diagnosed with inhalational anthrax and 7 with cutaneous anthrax 
(Table 1 and 2) (1–6). During the extensive epidemiologic investigation, >125,000 
clinical and environmental specimens were collected and analyzed for Bacillus anthracis, 
the causative agent of anthrax. We used the Laboratory Response Network (LRN) 
polymerase chain reaction (PCR) assay (real-time PCR assay) during the anthrax 
outbreak to detect B. anthracis DNA in environmental samples and clinical specimens. 
This assay provided 100% sensitivity and specificity when evaluated and validated on our 
panel of diverse bacterial isolates. On clinical specimens, this assay was one of three used 
to confirm anthrax cases when isolation of B. anthracis failed after antimicrobial drug 
treatment was initiated. In these culture-negative cases, laboratory confirmation was 
based on at least two supportive laboratory tests including this PCR, 
immunohistochemical stain (IHC), or anti-protective antigen (PA) titer (immunoglobulin 
[Ig]G enzyme-linked immunosorbent assay [ELISA]). PCR assays have not been 
previously used in an outbreak setting to detect B. anthracis directly in clinical specimens 
in a real-time manner. We evaluated the use of this assay on the clinical specimens and 
environmental samples received during the outbreak. 
Real-time PCR performance was evaluated by using clinical specimens collected 
from the nine confirmed cases of inhalational anthrax and seven confirmed cases of 
cutaneous anthrax identified during the bioterrorism-associated anthrax outbreak from 
October to December 2001. An effort was made to obtain the exact time of collection for 
each clinical specimen; however, when these data were not available, estimates were 
made based on other evidence from the medical record. A confirmed case of anthrax was 
defined as a clinically compatible case of cutaneous or inhalational illness that was either Publisher: CDC; Journal: Emerging Infectious Diseases 
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1) laboratory confirmed by isolation of B. anthracis from an affected tissue or site or 2) 
accompanied with other laboratory evidence of B. anthracis infection based on at least 
two supportive laboratory tests, including (a) evidence of B. anthracis DNA by PCR from 
specimens collected from an affected tissue or site, (b) demonstration of B. anthracis in a 
clinical specimen by IHC, or (c) fourfold rise in anti-PA IgG. Further testing will be 
necessary for full evaluation of the utility of these methods on clinical samples. However, 
as more specimens became available, the LRN PCR was used as part of the laboratory 
confirmation of anthrax in this outbreak setting. Although real-time PCR results were 
part of initial confirmation of the diagnosis in 2 patients, all 18 patients were 
subsequently found to have sufficient laboratory evidence (i.e., culture, serologic testing, 
or IHC) to confirm case status without considering real-time PCR assay results (Table 1 
and 2). In addition, 14 of 18 patients had sufficient laboratory evidence (i.e., real-time 
PCR, serologic testing, and IHC) to confirm case status without considering culture 
results (Table 1 and 2). 
During the course of the outbreak investigation, clinical specimens were available 
from 74 patients who had initial symptoms similar to those of anthrax, but in whom the 
diagnosis was excluded after further evaluation. The exclusion of the diagnosis in these 
patients was based on the following: 1) the subsequent clinical course was not consistent 
with anthrax, 2) no laboratory evidence of B. anthracis infection was found, and 3) 
patient had sufficient negative laboratory evidence to establish that the confirmed-case 
definition could not be met (i.e., negative culture results or negative results on at least 
two other supportive laboratory tests). 
The clinical performance of real-time PCR on clinical specimens was evaluated 
by using two approaches. In the first approach, traditional culture methods were used as 
the standard for evaluating real-time PCR detection of B. anthracis DNA in clinical 
specimens. In the second approach, the confirmed-case definition was used as the 
standard for comparing real-time PCR and traditional culture methods as diagnostic tests 
for anthrax. 
A total of 279 clinical specimens were tested in parallel fashion by both 
traditional culture methods and by real-time PCR (Table 3). Two aliquots were prepared Publisher: CDC; Journal: Emerging Infectious Diseases 
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from each specimen. From one aliquot DNA was extracted with a MagNa Pure LC 
instrument (Roche Diagnostics GmbH, Mannheim, Germany) by employing a DNA 
isolation kit I with the “High Performance” protocol. In addition, select specimens were 
extracted in duplicate with a Qiagen DNA Mini Kit (Qiagen, Valencia, CA) per 
manufacturer’s instructions. A second aliquot was used to inoculate bacteriological media 
for isolation of B. anthracis (7). 
Specimens from patients meeting the definition for confirmed anthrax and from 
those in whom the diagnosis was excluded were tested by LRN PCR assay and traditional 
culture using the methods described above. For specimens that were unavailable for 
testing at Centers for Disease Control and Prevention (CDC), culture results reported by 
the clinical laboratories of the patient’s treating facility were used for case confirmation. 
The performance of the LRN PCR assay was compared to that of traditional 
culture methods by testing environmental specimens collected from throughout the 
United States during the course of the outbreak by both methods. B. anthracis spores 
were eluted from swab specimens and other environmental samples in 2.5% pluronic F-
68 (Sigma, St. Louis, MO) and then collected by centrifugation through an Ultrafree-CL, 
0.45 uM, PVDF membrane filter (Millipore, Bedford, MA). Spores were eluted from the 
filters with 2.5% pluronic F-68, used to inoculate bacteriologic media, and added directly 
to real-time PCR assays without further purification or DNA extraction. 
Two hundred seventy-nine clinical specimens were tested by both culture and 
real-time PCR: 92 were from 9 patients with inhalational anthrax, 33 from 7 patients with 
cutaneous anthrax, 12 from 4 patients with suspect cutaneous anthrax, and the remaining 
142 from 74 patients in whom anthrax was excluded (Table 3). Of the 92 specimens from 
the inhalational anthrax cases, 5 (all blood specimens) were positive by both methods. Of 
the remaining 87, all were culture negative, but 29 (33%) were positive by the PCR 
assay. These included serum, sputum, pleural fluid, and tissue specimens (Table 3). Of 
the 33 specimens from the cutaneous anthrax cases, none were culture positive, but 
positive PCR results were obtained on a single blood specimen and two skin biopsy 
specimens. None of the 142 specimens from 74 patients without anthrax had positive 
results on culture or PCR. Publisher: CDC; Journal: Emerging Infectious Diseases 
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A total of 382 clinical specimens from 94 patients were tested by real-time PCR, 
culture, or both. Real-time PCR was performed on specimens from 14 patients with 
anthrax in whom the diagnosis could have been confirmed using non-PCR methods, 
including 9 inhalational anthrax patients and 5 cutaneous patients (2 were confirmed by 
culture, 3 by IHC and serology, and 2 by IHC and PCR). PCR was also performed on 
specimens from 74 patients in whom anthrax was excluded. 
Culture was performed on specimens from 13 anthrax patients in whom the 
diagnosis could be confirmed using non-culture methods, including 8 patients with 
inhalational anthrax and 5 patients with cutaneous anthrax. Culture was also performed 
on specimens from 74 patients in whom anthrax was excluded. 
One hundred forty-two specimens tested in the patients with inhalational anthrax 
included blood (n=74), serum (n=36), sputum (n=2), tissue (n=7), pleural fluid (n=19), 
and other (n=4). One hundred eighty-six specimens tested in the patients without anthrax 
included blood (n=74), swabs (n=15), serum (n=41), sputum (n=4), tissue (n=38), and 
other (n=14). 
Inhalational Cases 
Of the 11 patients with inhalational anthrax, 8 had blood cultures performed 
before the initiation of antimicrobial drug therapy, and cultures were positive in all eight 
at the hospital where patients were initially treated. At CDC, B. anthracis was also 
isolated from blood cultures of patient 5 (two blood cultures collected immediately before 
the start of the antimicrobial drug therapy), patient 6 (one blood culture collected on the 
same day antimicrobial drug therapy started),and patient 11 (two blood cultures collected 
the day before antimicrobial drug therapy). In contrast, 44 blood specimens were cultured 
from five patients (patients 2, 8, 9, 10, 11) (Table 1 and 2) after administration of 
antimicrobial drug therapy, and all were negative, including those from four patients 
(patients 2, 8, 10, 11) who had blood cultures obtained within 48 h of administration of 
antimicrobial drugs. Of the four patients (patients 2, 3, 5, 6) who had PCR performed on 
blood collected before the administration of antimicrobial drug therapy, all four had a 
positive PCR result (Table 4). In contrast, six patients had PCR testing of blood Publisher: CDC; Journal: Emerging Infectious Diseases 
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specimens collected after administration of antimicrobial drug therapy, and four (patients 
2, 8, 10, 11) had a positive PCR result. A single patient (patient 2) had blood cultures 
collected >5 days after antimicrobial agent administration; a total of 26 blood specimens 
were collected past day 5, and 8 were PCR positive, ranging from day 7 to day 10 
(Figure). 
Pleural fluid was available for testing from five patients (patients 1, 2, 8, 10, 11) 
with inhalational anthrax (Table 4). Of the pleural fluid specimens collected <5 days after 
the administration of antimicrobial drug therapy, none grew B. anthracis in culture, 
whereas all five had a positive PCR result. Pleural fluid specimens collected >5 days after 
antimicrobial agent administration were available only from a single patient (patient 2): 
all four of these specimens were PCR positive (Figure). 
Seven postmortem tissue specimens were collected from three patients. Samples 
from a lymph node and lung tissue from one patient (patient 10) and a lymph node 
sample from another patient (patient 11) were PCR positive. All others were negative 
(Table 4). 
Two sputum samples were tested. A sputum sample from patient 2 was received 5 
days after the administration of antimicrobial drugs, and it was PCR negative. The second 
sputum was obtained on day 2 after the administration of antimicrobial drugs and was 
PCR positive (patient 11). 
Of the seven patients with cutaneous anthrax, two had blood cultures performed 
before administration of antimicrobial drug therapy at the medical facility where patients 
were treated, and one patient had a positive result (Table 2, patient 5). All seven patients 
had blood cultures performed after initiation of antimicrobial drug therapy, and none had 
a positive result. All seven patients had PCR testing of blood specimens collected after 
administration of antimicrobial drug therapy, and of these, one was positive, from a 
patient with an extensive lesion and systemic complications of cutaneous anthrax. The 
blood sample was obtained 3 days after onset of the lesion. At the local facility, two 
patients had wound swabs obtained from ulcerative skin lesions before antimicrobial 
drugs were initiated; of these, one had evidence of gram-positive rods on Gram stain with 
B. anthracis isolated on culture (patient 7). Nine tissue samples were obtained from seven Publisher: CDC; Journal: Emerging Infectious Diseases 
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confirmed cases of cutaneous anthrax, including five patients with both fixed and frozen 
tissue and two patients with only fixed tissue. Eight samples were obtained after the 
administration of antimicrobial drugs. Culture was negative on all eight tissue samples; 
PCR was positive on one fixed tissue sample (patient 2), obtained 14 days after onset 
date, and on a fresh frozen tissue (patient 6) received 6 days after antimicrobial drugs 
were administered. In addition, one frozen tissue sample was received from a single 
patient before antimicrobial drug therapy; both culture and PCR were negative.Four 
additional cutaneous cases were defined as suspect because only one supportive 
laboratory test was positive; for three of the cases, serologic testing was positive, and for 
the fourth, IHC of an arm biopsy specimen was positive. A total of 12 specimens (7 blood 
specimens, 3 sera, 2 swabs) collected from these four patients were tested by PCR and 
culture; all were PCR and culture negative. 
Patients without Anthrax 
One hundred eighty-six clinical specimens were collected from 74 patients who 
were subsequently determined not to have either inhalational or cutaneous anthrax; 142 
specimens were culture and PCR negative (PCR specificity of 100%, 95% confidence 
interval 99% to 100%), and the remaining 44 tested by PCR only were also negative. 
Real-Time PCR in Environmental Specimens 
One hundred forty environmental specimens were analyzed by both culture and 
real-time PCR. A wide variety of samples were tested, including dust, paper towels, a 
syringe, vent filters, HVAC filters, vacuum cleaner debris, a cellulose sponge, and 
clothing; however, most samples were surface swabs (n=82). Of the 140 environmental 
specimens tested by both PCR and culture, 35 were positive by both methods, 7 were 
positive by culture only, and 4 were positive by PCR only. 
Discussion 
Isolation of B. anthracis from primarily sterile sites in culture has long been 
considered the standard of diagnosis for anthrax. However, this method is associated with 
a diagnostic delay of 12–24 h, and sensitivity is greatly diminished in the setting of prior Publisher: CDC; Journal: Emerging Infectious Diseases 
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antimicrobial administration (1). The LRN PCR was invaluable in diagnosing anthrax in 
patients when culturing B. anthracis failed and has rapidly become an integral part of the 
laboratory confirmation of anthrax. This real-time PCR also appears to be less affected by 
prior administration of antimicrobial drugs than culture, a property with important 
clinical ramifications. PCR positive results were obtained directly on clinical specimens, 
especially pleural fluids, in one case up to 11 days after the initiation of antimicrobial 
treatment. 
When the LRN PCR and culture were simultaneously performed on clinical 
specimens, PCR was positive in every specimen from which B. anthracis was isolated. 
PCR was also positive in an additional 29 (33%) specimens that were culture negative. 
All PCR-positive specimens were collected from patients in whom the diagnosis of 
anthrax was confirmed by other methods, suggesting that LRN PCR has a higher positive 
predictive value than culture. The LRN PCR also appears to have high clinical 
specificity; no positive tests on clinical specimens were collected from patients in whom 
the diagnosis of anthrax was considered, but ultimately ruled out based on clinical course 
and additional diagnostic tests. 
By using the confirmed case definition as the standard for diagnosis, the clinical 
performance characteristics of culture and LRN PCR during the 2001 outbreak can be 
directly compared to one another. Blood cultures appear to have a sensitivity of 100% (8 
of 8 patients) if collected before the administration of antimicrobial drug therapy in 
patients with inhalational anthrax, but the sensitivity falls to zero if the blood is collected 
after administration of antimicrobial drugs. Similarly, PCR assay of blood has a 
sensitivity of 100% (6 of 6 patients) if the blood is collected before antimicrobial drug 
therapy. In contrast to blood culture, PCR assay can detect B. anthracis in the blood after 
administration of antimicrobial drug therapy. However, the sensitivity seems to decrease 
within 24 h after initiation of antimicrobial drugs; three of four inhalational anthrax 
patients who had PCR assay performed on blood collected within 24 h of antimicrobial 
administration had a positive result, while one of five patients who had PCR performed 
on blood collected >24 h after the start of antimicrobial drug therapy had a positive result. Publisher: CDC; Journal: Emerging Infectious Diseases 
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The LRN PCR assay was particularly useful for testing pleural fluid specimens. 
No patient (n=5) in whom pleural fluid specimens were received at CDC had a culture 
positive result; however, all tests were performed after the administration of antimicrobial 
drug therapy. In contrast, all five patients who had the LRN PCR performed on pleural 
fluid specimens had a positive result including all three from whom pleural fluid was 
collected >24 hours after the administration of antimicrobial therapy. The sensitivity of 
the real-time LRN PCR on pleural fluid specimens appears to be less affected by the 
administration of antimicrobial drugs than does the LRN PCR of blood. 
Laboratory confirmation for the seven cutaneous cases primarily relied on IHC 
and serology as only two clinical samples (one blood and one tissue sample) from two 
patients grew B. anthracis at the medical facility where the patients were examined and 
treated. However, the LRN PCR was subsequently attempted on 11 blood samples and 8 
tissue samples from six cutaneous cases. Only one blood sample and two tissue samples 
from three patients were PCR positive (Table 3). CDC received all specimens from 
patients with cutaneous anthrax after the initiation of antimicrobial drug therapy. This 
success rate is similar to results of the LRN PCR on fluids (with the exception of pleural 
fluids) and tissue taken after the initiation of antimicrobial drug therapy on patients with 
inhalational anthrax. 
Overall, B. anthracis was isolated from 8 (73%) of 11 patients with confirmed 
inhalational anthrax while the LRN PCR was positive for 8 (89%) of 9 patients tested. 
One case in which only two blood cultures were tested yielded negative results for both 
culture and PCR. Of the seven patients with confirmed cutaneous anthrax, B. anthracis 
was isolated from two patients (29%), and the LRN PCR was positive for three (43%). 
One advantage of the LRN PCR assay is its rapidity; as a rule, results can be 
obtained within 1 h from the time samples have been prepared for testing. This rapid 
result is in striking contrast to the results for all other methods used for laboratory 
confirmation of anthrax. For example, standard culture methods require at least 24 h, 
while IHC results can be obtained within 8 h. On the other end of the spectrum is 
serology that requires paired sera collected at least 10 days apart, making this approach Publisher: CDC; Journal: Emerging Infectious Diseases 
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the least helpful in situations where therapeutic and public health decisions need to be 
instigated rapidly. 
Evaluation of the LRN PCR and its performance on clinical specimens was not 
conducted as a true prospective study as we were, to a degree, limited by the number and 
type of specimens available, as well as by the emergent response needed to establish the 
microbiologic diagnosis. However, the number and variety of clinical samples were 
substantial enough to allow statistically significant comparisons with the current 
standard, culture. Also, the fact that laboratory confirmation was obtained by either 
culture or a combination of other supportive laboratory methods allowed for case-based 
evaluation of the LRN PCR’s sensitivity and specificity. A major advantage of the LRN 
PCR was its lack of any false-positive results (100% specificity) when used on cultures 
and directly on clinical specimens. Of the 110 patients clinically suspected to have 
anthrax, 74 had clinical samples collected and tested by at least three diagnostic 
approaches (culture, PCR, IHC, or serology) that would allow for a case to be defined as 
confirmed (culture positive or two supportive tests positive) or suspect (one supportive 
case positive). Samples from all of these patients were negative in all tests applied, 
including this LRN PCR. Given the extent and cost of public health and other actions 
taken after the laboratory confirmation of each anthrax cases in this epidemic, a false-
positive PCR could have resulted in unnecessary waste of resources. 
In addition to its invaluable use on clinical specimens, the LRN PCR also allowed 
for the rapid analysis of hundreds of diverse environmental samples throughout the 
outbreak investigation. If present in these specimens, B. anthracis was in the form of 
spores. Because B. anthracis spores contain DNA on their surfaces as a result of the 
sporulation process, environmental specimens can be analyzed in the PCR assay without 
having to do the DNA extraction, which eliminates the need for complicated and usually 
inefficient spore lysis methods. Culture methods and LRN PCR results were in agreement 
92% (129/140) of the time. For the remaining 11 specimens, 4 were PCR positive and 
culture negative, and 7 were PCR negative and culture positive. The occasional 
discrepancies between culture and PCR could be due to inefficient removal of PCR Publisher: CDC; Journal: Emerging Infectious Diseases 
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inhibitors, detection of nonviable spores by PCR, and sampling error and volume effects 
when very few spores were present (5 µL for PCR vs. 100–200 µL for culture). 
The LRN PCR assay evaluated and validated in this study detects a B. anthracis–
specific chromosomal target as well as targets on both plasmids that are required for full 
virulence. This assay has served as an important aid in epidemiologic investigations of 
the recent bioterrorism-associated anthrax outbreak and was rapidly established as a 
valuable component of laboratory confirmation of anthrax cases. Highly specific results 
are obtained within a few hours of specimen arrival, making rapid and appropriate actions 
possible. At the same time, unnecessary panic and administration of antimicrobial drugs 
and vaccines were prevented when B. anthracis was rapidly excluded from differential 
diagnosis. 
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Figure. Results of polymerase chain reaction testing of clinical specimens (for which dates of 
collection were available) from a patient with inhalational anthrax (patient 2), are illustrated by 
date of collection relative to the initiation of antimicrobial drug therapy. Bacillus anthracis was not 
recovered from any of these specimens on which culture was attempted (data not shown). A. 
Blood, n=45; B. Pleural fluid, n=8. 
Table 1. Laboratory methods used for confirmation of 11 inhalational anthrax cases
a,b 
Patient 
no.
c  Laboratory confirmation  Other laboratory tests positive for Bacillus anthracis 
1  CSF culture  IHC of multiple (postmortem) tissues, blood culture 
2  PCR of pleural fluid; IHC of pleural fluid; serology Transbronchial  biopsy IHC, pleural biopsy IHC 
3  Blood culture  PCR of blood; serology 
4 Blood  culture  Serology 
5  Blood culture  IHC of mediastinal lymph nodes; PCR of blood 
6  Blood culture  IHC of mediastinal lymph nodes; PCR of blood 
7 Blood  culture  Serology 
8  PCR of pleural fluid; IHC of pleural fluid  Serology 
9  IHC of pleural fluid and bronchial biopsy; serology   
10  Blood and pleural fluid culture  IHC of multiple organs; PCR of multiple organs 
11  Blood culture  PCR of multiple organs; IHC of multiple organs 
aAll initial isolation of Bacillus anthracis from clinical specimens took place at the local health facility where the patients were treated. 
bCSF, cerebrospinal fluid; IHC, immunohistochemical stain; PCR, polymerase chain reaction. 
cPatients 1–10 described in Jernigan et al. (1) and patient 11 in Barakat et al. (5). 
 
Table 2. Laboratory methods used for confirmation of seven cutaneous anthrax cases
a,b 
Patient no.  Laboratory confirmation 
1  Chest biopsy IHC, serology 
2  Arm biopsy IHC and PCR, serology 
3  Arm biopsy IHC, serum PCR 
4  Face biopsy IHC, serology 
5 Blood  culture 
6  Forehead biopsy IHC and PCR 
7  Face biopsy culture 
aAll initial isolation of Bacillus anthracis from clinical specimens took place at the local health facility where the patients were treated.
bIHC, immunohistochemical stain; PCR, polymerase chain reaction. 
Table 3. Results of real-time PCR and culture testing performed on 382 clinical specimens
a,b 
  PCR only  PCR and culture   
Nine inhalational cases  +  -  PCR + C -  PCR + C +  PCR - C -  PCR - C +  Total 
Blood specimens  5  20  9  5  35  0  74 
Swab specimens  0  0  0  0  0  0  0 
Serum specimens  2  15  3  0  16  0  36 
Sputum specimens  0  1  1  0  0  0  2 
Tissue specimens  0  1  3  0  3  0  7 
Pleural fluid              
specimens 5  0  11  0  3  0  19 
Other specimens  1  0  2  0  1  0  4 
Totals 50  92  142       
Seven cutaneous cases              
Blood specimens  0  0  1  0  10  0  11 
Swab specimens  0  0  0  0  3  0  3 
Serum specimens  0  2  0  0  11  0  13 
Sputum specimens  0  0  0  0  0  0  0 
Tissue specimens  0  2  2  0  4  0  8 
Other specimens  0  0  0  0  2  0  2 
Totals 4  33  37       
Four suspect cases              
Blood specimens  0  2  0  0  7  0  9 
Swab specimens  0  0  0  0  2  0  2 
Serum specimens  0  1  0  0  3  0  4 
Sputum specimens  0  0  0  0  0  0  0 Publisher: CDC; Journal: Emerging Infectious Diseases 
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Tissue specimens  0  2  0  0  0  0  2 
 Other specimens  0  0  0  0  0  0  0 
Totals 5  12  17       
Other              
Blood specimens  0  16  0  0  58  0  74 
Swab specimens  0  1  0  0  14  0  15 
Serum specimens  0  11  0  0  30  0  41 
Sputum specimens  0  0  0  0  4  0  4 
Tissue specimens  0  14  0  0  24  0  38 
Other specimens  0  2  0  0  12  0  14 
Totals 44  142  186       
aSixteen patients with laboratory-confirmed anthrax, four suspect cases of anthrax, and 74 patients on whom anthrax has been ruled out.
bPCR, polymerase chain reaction; C, culture. 
Table 4. Results of real-time PCR and culture testing performed on 142 clinical specimens collected from nine patients 
with inhalational anthrax
a 
   Antimicrobial drug therapy    
Patient no.
b  Specimen type  Post therapy  Interval (days)  Culture  Real-time PCR 
1 Pleural  fluid
c Yes  3  Negative  Positive 
  Serum
c Yes  3  Negative  Negative 
  Serum
c Yes  3  Not  done  Negative 
  Pleural fluid
c Yes  4  Not  done  Positive 
  Pleural fluid
c Yes  4  Negative  Positive 
  Blood
c Yes  4  Not  done  Negative 
  Right lung tissue (frozen)
c Yes  4  Not  done  Negative 
  Heart blood
c Yes  4  Not  done  Negative 
  Pericardial fluid
c Yes  4  Not  done  Positive 
 2
c Blood  (5)     Not done  Positive 
  Blood (18)     Not done  Negative 
  Blood (5)     Negative Positive 
  Blood (21)     Negative Negative 
  Serum (2)     Not done  Positive 
  Serum (14)     Not done  Negative 
  Serum (2)     Negative Positive 
  Serum (13)     Negative Negative 
  Pleural fluid (3)     Not done  Positive 
  Pleural fluid (5)     Negative Positive 
  Pleural fluid (1)     Negative Negative 
  Body fluid (1)     Negative Negative 
  Respiratory wash (1)     Negative Positive 
  Sputum (1)     Not done  Negative 
3 Blood  culture  No  -1  Negative  Positive 
5 Blood  culture  No  0  Positive  Positive 
  Blood culture  No  0  Positive  Positive 
6 Blood  culture  No  0  Positive  Positive 
8 Blood  Yes  .5  Negative  Positive 
  Blood Yes  .5  Negative  Positive 
  Serum Yes  .5  Negative  Positive 
  Serum Yes  2  Negative  Negative 
  Pleural fluid  Yes  2  Negative  Positive 
  Pleural fluid  Yes  2  Negative  Positive 
  Blood Yes  37  Negative  Negative 
9 Blood  Yes  2  Negative  Negative Publisher: CDC; Journal: Emerging Infectious Diseases 
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  Blood Yes  2  Negative  Negative 
10 Pleural  fluid  Yes  1  Negative  Positive 
  Pleural fluid  Yes  1  Negative  Positive 
  Blood Yes  1  Negative  Positive 
  Thioglycolate broth
c Yes  3  Negative  Negative 
  CSF
c Yes  3  Negative  Positive 
  Lung tissue (frozen)
c Yes  3  Negative  Positive 
  Lymph node tissue (frozen)
c Yes  3  Negative  Positive 
11 Blood  culture  No  -1  Positive  Positive 
  Blood culture  No  -1  Positive  Positive 
  Sputum Yes  2  Negative  Positive 
  Body fluid/pleural fluid  Yes  2  Not done  Positive 
  Blood Yes  2  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Liver tissue (frozen)
c Yes  4  Negative  Negative 
  Lymph node tissue (frozen)
c Yes  4  Negative  Positive 
  Blood
c Yes  4  Negative  Negative 
  Pleural fluid
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Lung tissue (frozen)
c Yes  4  Negative  Negative 
  Spleen tissue (frozen)
c Yes  4  Negative  Negative 
  Blood
c Yes  4  Negative  Negative 
  Pleural fluid
c Yes  4  Negative  Negative 
aPCR, polymerase chain reaction  
bPatients 1–10 described in Jernigan et al. (1) and patient 11 in Barakat et al. (5). 
cSamples collected postmortem. 
dDue to the large number of samples from patient #2, samples were summarized by type and result in Figure. 
 